Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848042 · ClinicalTrials.gov registry record · NA
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
A NA study of Head and Neck Cancer, sponsored by Nanospectra Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT00848042: Completed NA study of Head and Neck Cancer, sponsored by Nanospectra Biosciences.
NCT00848042 is a NA study of Head and Neck Cancer that has completed, run by Nanospectra Biosciences. The registered enrollment target is 11 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00848042, a NA study of Head and Neck Cancer, has completed, sponsored by Nanospectra Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, multicenter, single-dose pilot study of AuroLase(TM) Therapy in the treatment of patients with refractory and/or recurrent tumors of the head and neck. Three (3) treatment groups of five (5) patients each will be enrolled and observed for six (6) months following treatment. Each group will receive a single dose of AuroShell(TM) particles followed by one or more interstitial illuminations with an 808nm laser. Particle dose and laser power may be increased in each dosing group.
Primary Outcome
Includes all participants that experienced an adverse device effect that were rated probable or definitely related to AuroShell particle infusion
Conditions Studied
Interventions
- DEVICE AuroLase Therapy
Study Locations (2)
Arizona
- Cancer Treatment Centers of American Western Regional Medical Center - Goodyear
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT00848042 record still lists
NCT00848042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which AuroLase Therapy is the first listed.
NCT00848042 reports a single indexed study location in Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT00848042 about?
NCT00848042 is a clinical study titled "Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck". This is an open-label, multicenter, single-dose pilot study of AuroLase(TM) Therapy in the treatment of patients with refractory and/or recurrent tumors of the head and neck. Three (3) treatment groups of five (5) patients each will be enrolled and observed for six (6) months following treatment. Ea...
What is the current status of trial NCT00848042?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2008-04. Estimated completion is 2014-08.
What conditions does trial NCT00848042 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00848042?
The interventions under investigation include: AuroLase Therapy (DEVICE).
Who is sponsoring clinical trial NCT00848042?
This trial is sponsored by Nanospectra Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848042 being conducted?
This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00848042's enrollment target sits among peer trials
11 237th of 250 higher than 14 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
RECRUITING · NA
-
Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck Dissection
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia